Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma;Tratamiento con hemodiálisis del fracaso renal agudo en el mieloma múltiple con filtros de alto poro (high cut off)

Nefrologia

Volumn 32, Issue 1, 2012, Pages 35-43

  Martín Reyes, Guillermo ^a   Toledo Rojas, Remedios ^a   Torres Rueda, Álvaro ^a   Sola Moyano, Eugenia ^a   Blanca Martos, Lourdes ^a   Fuentes Sánchez, Laura ^a   Martínez Esteban, M Dolores ^a   Ríos, M José Díez de los ^a   Bailén García, Alicia ^a   González Molina, Miguel ^a   García González, Isabel ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Acute renal failure; Haemodialysis; High cut off dialysers; Multiple myeloma

Indexed keywords

ACUTE KIDNEY FAILURE; AGED; ARTICLE; FEMALE; HUMAN; INSTRUMENTATION; MALE; MICROPORE FILTER; MIDDLE AGED; MULTIPLE MYELOMA; RENAL REPLACEMENT THERAPY;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MICROPORE FILTERS; MIDDLE AGED; MULTIPLE MYELOMA; RENAL DIALYSIS;

EID: 84858317584     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Nov.11094     Document Type: Article

References (28)

1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
2. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on prognosis. Eur J Haematol 2000;65:175-81.
3. Blade J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158:1889-93.
4. Winearls CG. Acute myeloma kidney. Kidney Int 1995;48:1347-61.
5. Magee C, Vella JP, Tormey W, Walshe JJ. Multiple myeloma and renal failure: One center's experience. Ren Fail 1998;20:597-606.
6. Innes A, Cuthbert RJ, Russell NH, Morgan AG, Burden RP. Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol 1994;16:149-56.
7. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998;13:1438-45.
8. Martín Reyes G, Valera A, Frutos MA, Ramos B, Ordóñez V, López de Novales E. Survival of myeloma patients treated with dialysis. Nefrologia 2003;23(2):131-6.
9. Sanders PW. Renal involvement in plasma cell dyscrasias. Curr Opin Nephrol Hypertens 1993;2(2):246-52.
10. Ivany. B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 1990;114:986-7.
11. Bouvet JP, Frot JC, Ducaylar A, Benlarhache C, Muller F. [Gammopathies with oligoclonal electrophoretic patterns. Incidence, immunochemical nature and association with neoplastic pathology]. Presse Med 1983;12:2511-4.
12. Sanders PW, Herrera GA, Chen A, Booker BB, Galla JH. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest 1988;82:2086-96.
13. Leboulleux M, Lelongt B, Mougenot B, Touchard G, Makdassi R, Rocca A, et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int 1995;48:72-9.
14. Basnayake K, Stringer SJ, Hutchison CA, Cockwell P. The biology of immunoglobulin free light chains and kidney injury. Kidney International 2011;79:1289-301.
15. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008;73:1282-8.
16. Dimopoulos MA, Richardson PG, Schlag R. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009;27(36):6086-93.
17. Clark, WF, Stewart, AK, Rock, GA, Sternbach M, Sutton DM, Barrett BJ, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005;143:777.
18. Hutchison CA, Bradwell A, Cook M, Basnayake K, Basu S, Harding S, et al. Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis. Clin J Am Soc Nephrol 2009;4(4):745-54.
19. Morgera S, Haase M, Kuss T, Vargas-Hein O, Zuckermann-Becker H, Melzar C, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006;34(8):2099-104.
20. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: In-vitro and in-vivo studies. J Am Soc Nephrol 2007;18:886-95.
21. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive automated immunoassay for immunoglobulin FLCs in serum and urine. Clin Chem 2001;47:673-80.
22. Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011;22:1129-36.
23. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988;33:1175.
24. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990;150:863-9.
25. Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs 2008;32(12):910-7.
26. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman Wh, Appel GB, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001;12:1482-92.
27. Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomized controlled trial. Trials 2008;9:55.
28. Grima DT, Hutchison CA. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney. Curr Med Res Opin 2011;27(2):383-91